Skip to content

RGENBioprocessing tools for life science

Repligen

By

Updated

Not investment advice. Kevin may own this stock. How we value stocks

History
Price
$163.81
Discount category
Close to intrinsic value
Analysts
Bullish
Next earnings
Feb 23 · · estimated
Pick status
Research only

In short

Thesis
The market weighs the steady bioprocessing growth of Repligen against new debt and the risks of the BioLife deal, and higher margins with growth in cell therapy through 2027 can lift its value.
Gap
Can close. The Q4 2026 report with 2027 guidance, expected in late February 2027, and the first year of BioLife show whether growth and margins rise as planned.

Company guidance: 2026 revenue $844 to $852 million; organic growth 12% to 13%; adjusted EPS $2.05 to $2.09 (, Q3 2026 results release (8-K))

Price history

About

Repligen Corporation (RGEN) is based in Waltham, Massachusetts. It makes bioprocessing products, such as filtration systems, chromatography products, proteins and analytics, that drug makers and contract manufacturers use to produce biologic drugs. On October 6, 2026, it bought BioLife Solutions, which makes cell processing tools for cell and gene therapy, for about $1.9 billion in cash and shares.

Revenue was $209.3 million in Q3 2026, and organic growth was 12.5%. The common stock trades on the Nasdaq in US dollars. Repligen files 10-K and 10-Q reports.

Thesis

The price of Repligen depends on whether bioprocessing demand keeps growing and whether BioLife adds the planned growth and margin. Revenue grew 12.5% organically in Q3 2026 and the company raised its 2026 revenue guidance to $844 million to $852 million, but it recorded a $41.2 million impairment of an intangible asset in Q3 2026, and it took on more debt for BioLife. For the price to rise, three things must be true. Orders for consumables and capital equipment must keep growing in 2027.

BioLife must grow with the cell therapy market and deliver the more than $20 million of first-year synergies that the company expects. The adjusted EBITDA margin must rise above the 2026 level of about 21%. The Q4 2026 report with 2027 guidance, expected in late February 2027, is the next test. If biotech funding or drug maker orders slow, the high valuation multiples of the sector can fall.

Checkpoints

  1. Feb 23, 2027 · est.Pending
    Q4 2026 results and 2027 guidance2026 revenue is in the guided range of $844 million to $852 million and 2027 guidance shows organic growth near 10% or more, and this passes; guidance for lower organic growth fails.
  2. Q3 2027 · est.Pending
    First year of BioLifeBioLife revenue grows and Repligen reports synergies of more than $20 million, and this passes; an impairment of BioLife assets fails.

Every passed and failed checkpoint across all picks

Recent events

  • November 6, 2026Repligen issued $1,000 million of 0.25% convertible notes due 2031 with a conversion price of about $226.37. Of these, $541.4 million was in exchange for $456.8 million of its 2028 notes, and $458.6 million was for cash. $143.2 million of the 2028 notes remain.
  • October 27, 2026Repligen reported Q3 2026 results. Revenue grew 11% to $209.3 million, 12.5% organically. The GAAP loss per share was $0.68, after an impairment of $41.2 million, and adjusted EPS was $0.53. It raised 2026 revenue guidance to $844 million to $852 million.
  • October 6, 2026Repligen completed the purchase of BioLife Solutions. BioLife stockholders received $11.25 in cash and 0.1442 Repligen shares per share, about $564 million in cash and 7.2 million shares in total.
Show 1 older event
  • July 21, 2026Repligen agreed to buy BioLife Solutions. The company said that the deal adds to revenue growth and margins and that it expects more than $20 million of synergies in the first year.

Latest news and filings

Last earnings
October 27, 2026 (8-K on sec.gov)
Next earnings
Expected about February 23, 2027. The company has not confirmed the date.

Every filing on SEC EDGAR (CIK 730272)

Risks

  • Demand depends on the spending of drug makers and biotech companies. Lower biotech funding or destocking by customers can cut orders.
  • The integration of BioLife can take more time and cost than planned, and the cell therapy market is still small.
  • Debt principal rose to about $1,143 million after the new convertible notes. The notes can add shares if the stock price rises above the conversion prices.
  • Repligen recorded a $41.2 million impairment of developed technology tied to a license agreement in Q3 2026.

Key statistics

Market cap
$10B
Shares of Oct 23, 2026
EPS (trailing)
-$0.21
12 months to Sep 30, 2026
52-week range
$100.99 – $198.87
To Nov 12, 2026
Beta
1.12
Vs S&P 500, 5 years monthly, to Oct 30, 2026
Average volume
1.2M
3 months, to Nov 12, 2026

Balance sheet

Cash
$863M
Debt
$600M
Net cash
$263M

Cash against debt

Cash$863M
Debt$600M

debt covered by cash

At September 30, 2026, Repligen had cash, cash equivalents and marketable securities of $863 million and 1.00% convertible notes due 2028 with a principal amount of $600 million. After that date, it paid about $564 million in cash for BioLife, issued $1,000 million of 0.25% convertible notes due 2031, of which $458.6 million was for cash, and retired $456.8 million of the 2028 notes.

Dividends

Repligen does not pay a dividend.

Source: company filings and market data, read on November 12, 2026.

Questions about Repligen

What does Repligen do?

Repligen Corporation (RGEN) is based in Waltham, Massachusetts. It makes bioprocessing products, such as filtration systems, chromatography products, proteins and analytics, that drug makers and contract manufacturers use to produce biologic drugs. Its market cap is $10B at the current price of $163.81.

When does Repligen report earnings next?

This is an estimate: Repligen may report on February 23, 2027. It last reported results on October 27, 2026.

Is Repligen stock below its intrinsic value?

Repligen stock is close to intrinsic value. This is general information, not advice.

What changed recently at Repligen?

The latest update is from November 6, 2026. Repligen issued $1,000 million of 0.25% convertible notes due 2031 with a conversion price of about $226.37.

What are the main risks for Repligen?

Demand depends on the spending of drug makers and biotech companies. The integration of BioLife can take more time and cost than planned, and the cell therapy market is still small. Debt principal rose to about $1,143 million after the new convertible notes.

How much debt and cash does Repligen have?

At September 30, 2026, Repligen had $600M of debt and $863M of cash.

Does Repligen pay a dividend?

No. Repligen does not pay a dividend.

Valuation against peers

CompanyP/E, last 4 quartersEV/EBITDA, last yearFree cash flow yield, last year10-year average P/E
RGENRepligenn/a75.9x0.9%n/a
TMOThermo Fisher Scientific35.4xn/a2.5%30.6x
WATWaters184.3xn/a1.2%27.5x
SNPSSynopsys69.3x52.3x1.8%48.9x
AZOAutoZone21.3xn/a3.5%17.7x
Peer median52.3xn/a2.2%n/a
  • Its free cash flow yield is 0.9%, 1.3 points below the peer median of 2.2%.

The peers are the companies on this site most like RGEN. The multiples come from company filings and today's price. There are no analyst forecasts: they all look back. EV/EBITDA is left out for banks, insurers and real estate companies. This is general information, not advice.

Similar companies

  • TMOThermo Fisher ScientificShares: High debt
    Intrinsic value
    Far above intrinsic value
    Gap
    Slow
  • MKKGYMerck KGaAShares: High debt
    Intrinsic value
    Close to intrinsic value
    Gap
    Can close
  • WATWatersShares: High debt
    Intrinsic value
    Far above intrinsic value
    Gap
    Can close
  • SNPSSynopsysShares: High debt
    Intrinsic value
    Below intrinsic value
    Gap
    Can close
  • AZOAutoZoneShares: High debt
    Intrinsic value
    Below intrinsic value
    Gap
    Can close

Loading your notes…

Read it all? Star RGEN or pass, then go on to the next one.